Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun 26:10:996.
doi: 10.3389/fonc.2020.00996. eCollection 2020.

Rare Primary Central Nervous System Tumors in Adults: An Overview

Enrico Franceschi  1 , Didier Frappaz  2 , Roberta Rudà  3 , Peter Hau  4 , Matthias Preusser  5 , Caroline Houillier  6 , Giuseppe Lombardi  7 , Sofia Asioli  8 , Caroline Dehais  9 , Franck Bielle  10 , Vincenzo Di Nunno  1 , Martin van den Bent  11 , Alba A Brandes  1 , Ahmed Idbaih  9 ; EURACAN Domain 10
Collaborators, Affiliations
Review

Rare Primary Central Nervous System Tumors in Adults: An Overview

Enrico Franceschi et al. Front Oncol. .

Abstract

Overall, tumors of primary central nervous system (CNS) are quite common in adults with an incidence rate close to 30 new cases/100,000 inhabitants per year. Significant clinical and biological advances have been accomplished in the most common adult primary CNS tumors (i.e., diffuse gliomas). However, most CNS tumor subtypes are rare with an incidence rate below the threshold defining rare disease of 6.0 new cases/100,000 inhabitants per year. Close to 150 entities of primary CNS tumors have now been identified by the novel integrated histomolecular classification published by the World Health Organization (WHO) and its updates by the c-IMPACT NOW consortium (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy). While these entities can be better classified into smaller groups either by their histomolecular features and/or by their location, assessing their treatment by clinical trials and improving the survival of patients remain challenging. Despite these tumors are rare, research, and advances remain slower compared to diffuse gliomas for instance. In some cases (i.e., ependymoma, medulloblastoma) the understanding is high because single or few driver mutations have been defined. The European Union has launched European Reference Networks (ERNs) dedicated to support advances on the clinical side of rare diseases including rare cancers. The ERN for rare solid adult tumors is termed EURACAN. Within EURACAN, Domain 10 brings together the European patient advocacy groups (ePAGs) and physicians dedicated to improving outcomes in rare primary CNS tumors and also aims at supporting research, care and teaching in the field. In this review, we discuss the relevant biological and clinical characteristics, clinical management of patients, and research directions for the following types of rare primary CNS tumors: medulloblastoma, pineal region tumors, glioneuronal and rare glial tumors, ependymal tumors, grade III meningioma and mesenchymal tumors, primary central nervous system lymphoma, germ cell tumors, spinal cord tumors and rare pituitary tumors.

Keywords: CNS lymphoma; embryonal tumor of central nervous system; germ cell tumors; glioneural tumor; medullobalstoma; mesenchymal non meningothelial intracranial tumors; pineal tumors; pituitary tumor.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. . The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. (2016) 131:803–20. 10.1007/s00401-016-1545-1 - DOI - PubMed
    1. Smoll NR, Drummond KJ. The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J Clin Neurosci. (2012) 19:1541–4. 10.1016/j.jocn.2012.04.009 - DOI - PubMed
    1. Franceschi E, Hofer S, Brandes AA, Frappaz D, Kortmann RD, Bromberg J, et al. . EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. Lancet Oncol. (2019) 20:e715–28. 10.1016/S1470-2045(19)30669-2 - DOI - PubMed
    1. Thompson EM, Hielscher T, Bouffet E, Remke M, Luu B, Gururangan S, et al. . Prognosticvalue of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncol. (2016) 17:484–95. 10.1016/S1470-2045(15)00581-1 - DOI - PMC - PubMed
    1. Packer RJ, Sutton LN, Elterman R, Lange B, Goldwein J, Nicholson HS, et al. . Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, vincristine chemotherapy. J Neurosurg. (1994) 81:690–8. - PubMed